查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012986

認知功能與記憶力增強藥物市場：按作用機制、劑型、應用、通路和最終用戶分類－2026-2032年全球市場預測

Cognitive & Memory Enhancer Drugs Market by Mechanism Of Action, Dosage Form, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年認知功能與記憶增強藥物的市值為71.3億美元，預計2026年將成長至78.4億美元，複合年成長率為10.95%，到2032年將達到147.7億美元。

主要市場統計數據
基準年 2025 71.3億美元
預計年份：2026年 78.4億美元
預測年份 2032 147.7億美元
複合年成長率 (%) 10.95%

對目前重塑認知功能和記憶增強藥物市場的療法、監管和商業性趨勢進行簡明扼要的策略性概述。

在認知和記憶增強藥物領域不斷發展的今天，臨床開發、商業化和政策制定者需要簡潔明了、切實可行的執行摘要。這些執行摘要提煉了治療分類、製劑多樣性、臨床應用、通路以及影響公共和公共部門決策的監管趨勢等方面的橫斷面資訊。本文檔旨在協助企業確定研發優先順序、最佳化產品組合、制定打入市場策略並增強供應鏈韌性。

科學進步、不斷變化的法規以及數位醫療的融合，是如何重新定義認知療法的發展路徑和價值的？

認知和記憶增強療法領域正經歷著一場變革，其驅動力包括神經科學的跨學科進展、監管機構對真實世界數據（REW）的重視以及藥物獲取模式的改變。我們對突觸可塑性和神經傳導物質調節的科學理解不斷加深，推動治療假設超越單一標靶策略，催生出一系列聯合治療和仿單標示外用藥策略。同時，監管機構也日益重視適應性試驗設計和以患者為中心的終點指標，從而加快了進行性神經退化性疾病和神經發育障礙的療效和安全性評估進程。

美國近期關稅對認知療法藥品採購、供應鏈韌性和監管時限的實際影響

美國關稅和貿易政策的發展對整個醫藥價值鏈的供應鏈規劃和成本結構產生了重大影響。影響活性成分、中間體和包裝材料的關稅措施增加了採購的複雜性，並促使製造地進行地理多元化。對於以往依賴集中採購的公司而言，這些變化凸顯了供應商選擇、庫存緩衝和近岸外包等策略對於維持業務永續營運和控制成本風險的重要性。

將作用機制、製劑選擇、臨床應用、通路和最終用戶趨勢與策略重點連結起來的詳細細分洞察。

細分市場分析揭示了治療藥物的研發和商業化策略應如何根據作用機制、製劑、臨床適應症、通路和終端用戶環境進行客製化。就作用機製而言，以膽鹼酯酶抑制劑（如多奈哌齊、Galantamine他敏和Rivastigmine）為重點的項目往往強調適度的症狀緩解效果和已確立的安全性，從而促進漸進式創新和更廣泛的適應症。另一方面，NMDA受體拮抗劑則需要謹慎的給藥和監測策略，以關注其神經生理效應。精神興奮劑的研發分為安非他命和哌甲酯類，前者優先考慮嚴格的濫用風險降低和長期安全性監測。吡拉西坦和Piracetam類藥物通常定位於認知增強和輔助性治療等細分領域，因此需要獨特的臨床試驗設計和市場推廣策略。

美洲、歐洲、中東、非洲和亞太地區的地理差異如何影響監管策略、臨床實踐和商業化順序？

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的研發合作機會、監管方式和打入市場策略。在美洲，研究生態系統和以支付方主導的准入模式營造了一種優先考慮嚴謹臨床證據和支付方參與的環境，有利於那些能夠產生令人信服的結果數據和衛生經濟學論證的項目。區域內的跨國合作支持快速進行研究者主導的試驗和官民合作關係，加速臨床檢驗。

結合科學創新、監管應對力和夥伴關係主導的商業化：一家公司建立強大的認知療法藥物組合的策略選擇。

認知和記憶增強領域的企業策略體現了創新投資、產品組合多元化和策略夥伴關係之間的平衡。主要企業正透過與科技公司在數位生物標記方面建立合作關係，並尋求許可和共同開發契約以獲得互補的作用機制，從而擺脫對單一分子療法的依賴。這種多元化降低了臨床和監管方面的集中風險，同時能夠提供更全面的治療方案，將藥理學與數位療法和監測平台結合。

透過協調證據產生、供應鏈韌性、監管靈活性和相關人員參與，採取策略性和實用性措施來加速產品採用。

產業領導企業應優先考慮整合證據策略，使早期研發與保險公司和臨床醫生在應用過程中優先考慮的資料類型保持一致。投資於能夠捕捉功能性和患者報告結果的臨床終點，有助於加強報銷談判，並推動長期應用。此外，將數位化評估工具納入臨床試驗和上市後項目，可以獲得更豐富的縱向數據，並創造更具吸引力的價值提案。

結合專家訪談、臨床和監管證據整合以及供應鏈情境分析的混合調查方法，得出可操作的見解。

本分析的研究途徑整合了定性專家訪談、監管文件審查、臨床文獻整合和供應鏈圖譜分析，以提供多角度的檢驗。主要資訊來源包括對臨床醫生、監管專家、採購負責人和生產負責人進行的結構化訪談，以了解當前的決策者和營運限制。次要資訊來源包括同行評審的臨床研究、公開的監管決策、臨床試驗註冊資訊和企業資訊披露信息，以檢驗臨床和戰略層面的敘述。

認知療法成功的關鍵決定因素是證據的整合、營運的多樣化以及策略挑戰的整合，強調相關人員。

總之，在科學進步、監管機構日益重視療效指標以及供應鏈和政策考量的推動下，認知和記憶增強藥物領域正朝著更一體化的治療和給藥模式轉變。能夠將針對特定機制的研發與製劑策略、循證途徑和分銷實際情況相結合的機構，將更有利於將臨床潛力轉化為永續的患者可及性。同時，積極主動的規劃和跨部門合作對於應對貿易政策和區域監管差異等外部因素至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：認知功能與記憶增強藥物市場－依作用機制分類

  • 膽鹼酯酶抑制劑
    • 完成 pezil
    • Galantamine
    • Rivastigmine
  • NMDA拮抗劑
  • 精神興奮劑
    • 安非他命
    • 哌甲酯
  • 拉塞圖姆
    • 安尼拉塞圖姆
    • Piracetam

第9章：按劑型分類的認知功能與記憶增強藥物市場

  • 膠囊
  • 注射藥物
  • 口服粉劑
  • 藥片

第10章：認知功能與記憶增強藥物市場：依應用領域分類

  • 阿茲海默症
  • 注意力不足過動症（ADHD）
  • 整體認知能力提升
  • 帕金森氏症

第11章 認知功能與記憶增強藥物市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 認知功能與記憶增強藥物市場：依最終使用者分類

  • 診所
  • 醫院

第13章 認知功能與記憶增強藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 認知功能與記憶增強藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 認知功能與記憶增強藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國認知功能與記憶增強藥物市場

第17章：中國認知功能與記憶增強藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Allergan Plc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lundbeck A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
Product Code: MRR-431418DA4906

The Cognitive & Memory Enhancer Drugs Market was valued at USD 7.13 billion in 2025 and is projected to grow to USD 7.84 billion in 2026, with a CAGR of 10.95%, reaching USD 14.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.13 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 14.77 billion
CAGR (%) 10.95%

A concise and strategic orientation to the therapeutic, regulatory, and commercial dynamics reshaping cognitive and memory enhancement therapeutics today

The evolving landscape of cognitive and memory enhancer drugs demands concise, actionable synthesis for leaders across clinical development, commercialization, and policy. This executive summary distills cross-cutting insights about therapeutic classes, formulation diversity, clinical applications, distribution pathways, and regulatory dynamics that shape decision-making across private and public sectors. It is written to inform R&D prioritization, portfolio optimization, market entry strategies, and supply chain resilience efforts.

Beyond therapeutic specifics, the summary highlights systemic forces such as research innovation, changing clinician and patient expectations, and geopolitical trade dynamics that intersect with drug development and access. The aim here is not to provide exhaustive data tables but to articulate the most salient patterns, risks, and opportunities. This approach helps stakeholders synthesize complex evidence into pragmatic next steps, ensuring that clinical promise can be translated into viable products and responsible deployment while maintaining regulatory compliance and patient safety.

How converging scientific advances, regulatory evolution, and digital health integration are redefining development pathways and value assessment for cognitive therapeutics

The landscape for cognitive and memory enhancement therapeutics is undergoing transformative shifts driven by convergent advances in neuroscience, regulatory emphasis on real-world evidence, and changing models for drug access. Scientific progress in understanding synaptic plasticity and neurotransmitter modulation has broadened therapeutic hypotheses beyond single-target approaches, prompting a wave of combination and repurposing strategies. Concurrently, regulators are increasingly receptive to adaptive trial designs and patient-centric endpoints, which is accelerating how efficacy and safety are assessed in progressive neurodegenerative and neurodevelopmental indications.

In parallel, payers and health systems are redefining value, prioritizing measures of functional improvement and long-term outcomes over short-term symptomatic relief. Digital health has emerged as a force multiplier, enabling remote cognitive assessment and adherence monitoring, which in turn supports decentralized clinical trials and extended post-market surveillance. As a result, sponsors must adapt by integrating translational science with pragmatic evidence generation and by forging partnerships that span technology, clinical care, and supply chain stakeholders. These shifts demand more agile development pathways and a heightened focus on demonstrable patient benefit across heterogeneous care settings.

Practical implications of recent United States tariff measures on pharmaceutical sourcing, supply chain resilience, and regulatory timing for cognitive therapeutics

United States tariffs and trade policy developments have created material considerations for supply chain planning and cost structures across the pharmaceutical value chain. Tariff actions affecting active pharmaceutical ingredients, intermediates, and packaging components increase procurement complexity and incentivize geographic diversification of manufacturing footprints. For companies that relied on concentrated sourcing, these shifts have elevated the importance of supplier qualification, inventory buffering, and nearshoring as strategies to maintain continuity and control cost exposure.

Moreover, tariffs interact with regulatory timelines and lead times for site inspections, which can compound delays in product launches or lifecycle management activities. In response, manufacturers are investing in cross-border regulatory intelligence and scenario planning to anticipate customs and compliance impacts. Payers and procurement bodies are also reassessing pricing frameworks to reflect underlying supply chain risk. Taken together, the tariff environment reinforces the need for integrated planning across procurement, regulatory affairs, and commercial teams to safeguard access and maintain competitive positioning.

Deep segmentation insights linking mechanism of action, formulation choices, clinical applications, distribution pathways, and end-user dynamics to strategic priorities

Insight into segmentation reveals how therapeutic development and commercialization strategies must be tailored to mechanism, formulation, clinical indication, distribution pathway, and end-user setting. With respect to mechanism of action, programs focusing on cholinesterase inhibitors, including donepezil, galantamine, and rivastigmine, tend to emphasize modest symptomatic benefits and established safety profiles that favor incremental innovation and label expansion, whereas NMDA antagonists require careful dosing and monitoring strategies tied to neurophysiological effects. Psychostimulant development split into amphetamine and methylphenidate approaches prioritizes rigorous abuse potential mitigation and long-term safety surveillance, while racetam derivatives like aniracetam and piracetam often position themselves within cognitive enhancement and adjunctive therapy niches, prompting distinct clinical trial designs and marketing claims.

Formulation strategy matters: the choice among capsules, injectables, oral powders, and tablets shapes patient adherence, distribution logistics, and manufacturing considerations. Indication-specific pathways vary substantially as well; therapeutic approaches for Alzheimer's disease demand robust evidence on disease modification and functional outcomes, whereas attention deficit hyperactivity disorder programs prioritize pediatric safety and sustained efficacy, general cognitive enhancement initiatives navigate ethical and regulatory scrutiny, and Parkinson's disease applications integrate motor and non-motor symptom endpoints. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies each impose different regulatory oversight, reimbursement interfaces, and patient access patterns, which in turn affect commercialization tactics. Finally, end users concentrated in clinics and hospitals emphasize institutional formularies, physician education, and hospital-level procurement processes, underscoring the need for targeted stakeholder engagement and evidence dissemination frameworks.

How geographic variation across the Americas, Europe Middle East and Africa, and Asia Pacific dictates regulatory strategy, clinical operations, and commercialization sequencing

Regional dynamics shape R&D collaboration opportunities, regulatory approaches, and market access strategies across the Americas, Europe Middle East and Africa, and Asia Pacific. In the Americas, research ecosystems and payer-driven access models create environments that prioritize rigorous clinical evidence and payer engagement, which favors programs that generate compelling outcomes data and health economic justification. Cross-border collaboration within the region supports rapid investigator-initiated studies and public-private partnerships that accelerate clinical validation.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varied reimbursement frameworks necessitate tailored country-level strategies that balance centralized regulatory pathways with local evidence generation. This region also presents opportunities for multi-jurisdictional post-market surveillance and adaptive launch sequencing. The Asia Pacific region combines rapidly evolving clinical research capacity with manufacturing scale, enabling sponsorship models that leverage local trial enrollment and cost-efficient production; however, regional regulatory expectations and clinical practice patterns require careful alignment to ensure successful adoption and reimbursement. Together, these geographic considerations inform where to locate trial activity, align manufacturing, and prioritize market entry sequencing based on clinical, regulatory, and commercial fit.

Corporate strategic choices that combine scientific innovation, regulatory readiness, and partnership-led commercialization to build resilient cognitive therapeutic portfolios

Corporate strategies within the cognitive and memory enhancement space reflect a balance of innovation investment, portfolio diversification, and strategic partnerships. Leading organizations are expanding beyond single-molecule bets by cultivating collaborative agreements with technology firms for digital biomarkers, and by pursuing licensing or co-development arrangements to access complementary mechanisms of action. This diversification reduces clinical and regulatory concentration risk while enabling more comprehensive therapeutic offerings that combine pharmacology with digital therapeutics or monitoring platforms.

Operationally, companies are strengthening regulatory affairs capabilities to navigate evolving evidentiary expectations and are enhancing pharmacovigilance systems to support long-term safety monitoring. On the commercial front, competitive differentiation increasingly stems from robust provider education, real-world evidence programs that demonstrate functional benefit, and targeted access strategies for institutional buyers. Smaller firms and academic spinouts often position themselves for strategic partnership or acquisition by prioritizing clean intellectual property, clear clinical differentiation, and manufacturable formulations that can integrate into larger organizations' distribution networks.

Strategic and operational actions that align evidence generation, supply chain resilience, regulatory agility, and stakeholder engagement to accelerate product adoption

Industry leaders should prioritize integrated evidence strategies that align early-stage development with the types of data payers and clinicians value for adoption. Investment in clinical endpoints that capture functional outcomes and patient-reported measures will strengthen reimbursement discussions and support long-term uptake. In addition, embedding digital assessment tools into trials and post-market programs can produce richer longitudinal data and enable more persuasive value narratives.

From an operational perspective, companies must diversify sourcing and qualify alternate suppliers for critical ingredients to mitigate geopolitical and tariff-related disruption. Regulatory agility should be bolstered through adaptive trial designs, proactive dialogue with authorities, and readiness to deploy real-world evidence to address emerging safety or effectiveness questions. Commercial teams should engage hospital and clinic stakeholders early, tailoring messaging to institutional formulary processes and clinician practice patterns. Finally, pursuing strategic alliances with technology providers, contract manufacturers, and regional partners can reduce time-to-market and expand delivery options for patients across heterogenous healthcare environments.

A blended methodology combining expert interviews, clinical and regulatory evidence synthesis, and supply chain scenario analysis to generate actionable intelligence

The research approach underpinning this analysis integrates qualitative expert interviews, regulatory document review, clinical literature synthesis, and supply chain mapping to triangulate insights. Primary inputs included structured interviews with clinicians, regulatory specialists, procurement officers, and manufacturing leaders to capture current decision drivers and operational constraints. Secondary sources encompassed peer-reviewed clinical studies, publicly available regulatory determinations, clinical trial registries, and company disclosures to validate clinical and strategic narratives.

Analytical methods emphasized cross-validation across data streams and scenario analysis to explore the implications of regulatory shifts, tariff changes, and commercialization choices. Particular attention was paid to methodological transparency, including documentation of interview guides, data collection dates, and criteria for inclusion of regulatory and clinical materials. This blended methodology ensures that conclusions reflect both practitioner perspectives and objective documentary evidence, producing actionable insights while acknowledging areas where additional primary data would further reduce uncertainty.

Synthesis of strategic imperatives highlighting evidence integration, operational diversification, and stakeholder alignment as determinants of success in cognitive therapeutics

In conclusion, the field of cognitive and memory enhancers is moving toward more integrated therapeutic and delivery paradigms driven by scientific progress, regulatory emphasis on meaningful outcomes, and heightened supply chain and policy considerations. Organizations that align mechanism-specific development with formulation strategies, evidence pathways, and distribution realities will be better positioned to translate clinical promise into sustainable patient access. At the same time, external forces such as trade policy and regional regulatory variation require proactive planning and cross-functional coordination.

Moving forward, success will favor sponsors who invest in rigorous, patient-centered evidence, diversify operational dependencies, and engage stakeholders across clinicians, institutions, and payers early in the development cycle. By doing so, they can not only mitigate risk but also create compelling value propositions that support adoption in diverse healthcare settings. These priorities should inform actionable roadmaps for research, manufacturing, and commercialization teams seeking to make meaningful progress in therapeutic areas where clinical need and scientific opportunity converge.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cognitive & Memory Enhancer Drugs Market, by Mechanism Of Action

  • 8.1. Cholinesterase Inhibitors
    • 8.1.1. Donepezil
    • 8.1.2. Galantamine
    • 8.1.3. Rivastigmine
  • 8.2. NMDA Antagonists
  • 8.3. Psychostimulants
    • 8.3.1. Amphetamines
    • 8.3.2. Methylphenidate
  • 8.4. Racetams
    • 8.4.1. Aniracetam
    • 8.4.2. Piracetam

9. Cognitive & Memory Enhancer Drugs Market, by Dosage Form

  • 9.1. Capsules
  • 9.2. Injectable
  • 9.3. Oral Powder
  • 9.4. Tablets

10. Cognitive & Memory Enhancer Drugs Market, by Application

  • 10.1. Alzheimer's Disease
  • 10.2. Attention Deficit Hyperactivity Disorder
  • 10.3. General Cognitive Enhancement
  • 10.4. Parkinson's Disease

11. Cognitive & Memory Enhancer Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Cognitive & Memory Enhancer Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals

13. Cognitive & Memory Enhancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cognitive & Memory Enhancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cognitive & Memory Enhancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cognitive & Memory Enhancer Drugs Market

17. China Cognitive & Memory Enhancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Allergan Plc
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Biogen Inc
  • 18.10. Eisai Co., Ltd
  • 18.11. Eli Lilly and Company
  • 18.12. GlaxoSmithKline plc
  • 18.13. Johnson & Johnson
  • 18.14. Lundbeck A/S
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Pfizer Inc
  • 18.18. Roche Holding AG
  • 18.19. Sanofi S.A.
  • 18.20. Takeda Pharmaceutical Company Limited
  • 18.21. Teva Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GALANTAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GALANTAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ANIRACETAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ANIRACETAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ANIRACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PIRACETAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PIRACETAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PIRACETAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ORAL POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ORAL POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GENERAL COGNITIVE ENHANCEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GENERAL COGNITIVE ENHANCEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GENERAL COGNITIVE ENHANCEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 171. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)